15 December 2016, Newcastle upon Tyne
QuantuMDx today announced the appointment of CEO Elaine Warburton OBE to the Precision Medicine Catapult Board of Directors as Non Executive Director. Recognised with an OBE in 2014 for her services to Innovation in Healthcare, Elaine will bring 25 years’ of experience in healthcare and biotechnology to the board alongside first-hand experience of the challenges an SME faces when developing and introducing a disruptive technology or a new therapeutic into mainstream medicine.
The Precision Medicine Catapult’s (PMC) aim is to establish the UK as the national and international leader and convenor of the precision medicine industry – developing the industry at scale to deliver safe, reliable and efficient treatments to meet patients’ personalised needs at affordable cost. Working with companies, charities, academia, policy makers, hospitals, patient groups and healthcare authorities in these clusters and internationally, the PMC will provide the leadership to grow the industry while delivering local healthcare impact.
QuantuMDx’s CEO Elaine Warburton OBE said “It is an honour to have been appointed to the Precision Medicine Catapult Board of Directors. With 1 in 2 people born in the UK after 1960 diagnosed with cancer during their lifetime, including myself, the Catapult’s work is vital. The PMC is helping develop the UK’s precision medicine industry to ensure every patient has access to the right diagnostics, therapeutics and therapies at the right time and at an affordable cost, enabling patients to continue to lead long and fruitful lives. I am looking forward to contributing to and furthering the PMC’s vision.”
PMC Chairman, Professor Richard Barker OBE, said: “We’re delighted to be strengthening our board with Elaine, Sir Alex Markham, Dr Mike Evans and Paul Blackburn, who collectively provide in-depth financial and SME leadership experience, and complement the tremendous scientific, clinical and NHS skills we already have on the PMC board. I’m very confident that all four of our new non-execs will be great assets to the PMC and positively impact the strategy and future direction of the Catapult.”
For press enquiries please contact
Maggie Love, Marketing Manager, QuantuMDx Group
0870 803 1234
About Elaine Warburton
Elaine Warburton OBE is an entrepreneur with over 25 years’ healthcare and biotechnology experience. With an eclectic background in nursing, genetics, accounting and running hospitals, she currently heads up pioneering British technology company, QuantuMDx Group. QuantuMDx is developing Q-POC™, a low-cost molecular diagnostic device that could be used to test patients in the field and provide comprehensive analyses, answering clinical questions fast. Elaine was awarded an OBE in the 2014 Queen’s New Year Honours for services to innovation in healthcare.
About QuantuMDx Group
Improving global healthcare by developing transformative technologies that will enable rapid, accurate and affordable diagnostic testing in the community.
QuantuMDx Group is a multinational technology developer headquartered in the United Kingdom, with operations and partners in the United States, Asia, Europe and Africa.
The company’s flagship product Q-POC™’s superior testing capabilities will bring the power of precision medicine to health professionals globally, enabling immediate detection of antimicrobial resistance and subsequent ‘right first time prescribing’.
QuantuMDx was co-founded by CEO Elaine Warburton OBE, inventor and CSO Jonathan O’Halloran and CFO Julian Warburton. Fellow Board members include CMO Professor Sir John Burn, COO Dr Sam Whitehouse and President of QuantuMDx USA Paul Fitzpatrick. Prof Sanjeev Krishna chairs the Infectious Disease Advisory Committee.
QuantuMDx is a privately owned company with a strongly humanitarian focus.
About the Precision Medicine Catapult
The Precision Medicine Catapult (PMC) is innovating to build a world-leading, UK-based, precision medicine industry. It will establish this at pace and scale so that is safe, reliable and efficient in delivering targeted treatments to meet patients’ personalised needs, at an affordable cost. The PMC is headquartered in Cambridge, with national and regional Centres of Excellence across the UK. Working with companies, charities, academia, policy makers, hospitals, patient groups and healthcare authorities in these clusters and internationally, it will provide the leadership to grow the industry while delivering local health care impact. The PMC was established in April 2015. It is a company limited by guarantee and is part-funded by Innovate UK, the Government’s innovation agency. It is one of 11 Catapults which form a network of world-leading centres transforming the UK’s capability to translate innovation into products that drive economic growth in the UK’s high-potential industrial sectors.